NEW YORK, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating
potential claims against Ekso Bionics Holdings, Inc. (“Ekso Bionics” or the “Company”) (NASDAQ:EKSO).
On December 14, 2017, Ekso Bionics advised investors that “the Company’s internal control over financial reporting as of
December 31, 2016 should no longer be relied upon and that a material weakness in the Company's internal control over financial
reporting existed as of such date.” Then on December 27, 2017, the Company filed an amended annual report for 2016 and
amended quarterly reports for the first three quarters of 2017.
On this news, Ekso Bionics’ share price declined.
If you invested in Ekso Bionics stock or options and would like to discuss your legal rights,
click here: www.faruqilaw.com/EKSO. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at
212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.
CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to
discuss your particular case. All communications will be treated in a confidential manner.
